Nanotechniques Inactivate Cancer Stem Cells

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Nanomedicine

Background:

• Cancer stem cells (CSCs) are crucial for tumor growth and recurrence.
• Identifying CSCs and developing targeted therapies is a key challenge in oncology.
• Ehrlich carcinoma serves as a model to study CSCs and their therapeutic inhibition.

Purpose of the Study:

• To characterize Ehrlich carcinoma cells and identify CSCs.
• To evaluate the therapeutic potential of novel hybrid nanocomplexes for cancer treatment.
• To investigate the role of CD44+ and CD44- subpopulations in tumor growth.

Main Methods:

• Phenotypic characterization of Ehrlich carcinoma cells.
• Assessment of tumorigenic activity of CD44+ and CD44- subpopulations.
• Treatment with hybrid nanocomplexes (GdYVO4:Eu3+ and cholesterol).
• Flow cytometry analysis of cell subpopulations (CD44, CD24, CD117).

Main Results:

• Ehrlich carcinoma contains CSCs, with CD44+ cells exhibiting significantly higher tumorigenic activity (tenfold) than CD44- cells.
• CD44+ cells generated CD44high, CD44+CD24-, and CD44+CD24+ subpopulations, confirming CSC presence.
• Hybrid nanocomplex treatment reduced CD44high cells and increased CD117+ cells.
• Tumor growth intensity was reduced by 74.70% ± 4.38% in the treated group compared to the control.

Conclusions:

• Cancer stem cells are present in Ehrlich carcinoma and are enriched within the CD44+ subpopulation.
• Synthesized hybrid nanocomplexes demonstrate significant tumor-inhibiting effects.
• These nanocomplexes offer a promising therapeutic strategy by targeting cancer stem cells in Ehrlich carcinoma.